We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: Randomized controlled clinical trial.
- Authors
Ahmed Hassan, Samar Osama; El-Din Hassan, Ahmed Nour; Mohamed, Manal Sabry; Al Ashram, Mohamed Nabil Badawy; Nesim, Mina Michael; Allam, Mohamed Farouk
- Abstract
Background: Coronavirus disease 2019 (COVID-19) is a newly emerging human disease caused by a novel coronavirus, causing a global pandemic crisis. Probiotics and/or colchicine may be considered as options for treatment since they have anti-viral, antiinflammatory, and immunomodulatory effects. Methods: A total of 150 patients with mild and moderate severity of COVID-19 were randomly enrolled in the study,50 patients in each arm. Results: around one third (34.7%) of the participants were aged between 29 and 39 years; one-quarter (24.7%) were aged between 18 and 28 years and 40.6% were aged 40 years and above. The mean duration of symptoms improvement was 12, 11 and 12 in the colchicine, probiotic, and control groups, respectively. Improvement of inflammatory markers over time occurred in each of the three groups, with no statistically significant difference between them. Conclusion: Probiotic Lactobacillus acidophilus and colchicine shows no significant effect on the symptoms, duration, and progression of mild and moderate cases of COVID-19.
- Subjects
LACTOBACILLUS acidophilus; COVID-19 pandemic; CLINICAL trials; RANDOMIZED controlled trials; COVID-19
- Publication
Microbes & Infectious Diseases, 2024, Vol 5, Issue 3, p901
- ISSN
2682-4132
- Publication type
Academic Journal
- DOI
10.21608/MID.2024.281579.1877